Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 18/20 | 0.38 |
| ▸ | PPARA | Q07869 | 17/20 | 0.38 |
| ▸ | PPARD | Q03181 | 2/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6293717 | 0.79 | PPARG (0.50) | PPARGPPARAPPARD | |
| SCHEMBL821405 | 0.79 | PPARG (0.59) | PPARGPPARAPPARDKDM4E | |
| SCHEMBL13847874 | 0.78 | KDM1A (0.36) | PPARGPPARAPPARDKDM4E | |
| SCHEMBL6293043 | 0.78 | TP53 (0.37) | PPARGPPARAPPARDPTPN1 | |
| SCHEMBL31094992 | 0.77 | PPARG (0.40) | PPARGPPARAPPARDKDM4E | |
| SCHEMBL31095024 | 0.77 | PPARG (0.46) | PPARGPPARAPPARDKDM4E | |
| SCHEMBL3578702 | 0.77 | PPARG (0.55) | PPARGPPARAPPARDKDM4E | |
| SCHEMBL6601904 | 0.77 | HSD17B10 (0.53) | PPARGPPARA | |
| SCHEMBL6293798 | 0.77 | PPARA (0.53) | PPARGPPARAPPARD | |
| SCHEMBL6289729 | 0.76 | MEN1 (0.53) | PPARGPPARAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131372-A1 | PHOSPHONATE ANALOGS FOR TREATING METABOLIC DISEASES | CHEN JAMES M | 2009-05-21 | — | — | US | disclosed |
| US-7407965-B2 | Phosphonate analogs for treating metabolic diseases | GILEAD SCIENCES, INC. (US) | 2008-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131372-A1 | PHOSPHONATE ANALOGS FOR TREATING METABOLIC DISEASES | PHOSPHO1, G6PC1, PC | PPARG 314/4885PPARA 234/4885PPARD 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.